Page last updated: 2024-11-06

amizyl

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID66448
CHEMBL ID1584883
SCHEMBL ID4419579
MeSH IDM0002302

Synonyms (112)

Synonym
MLS001148661
MLS000069801 ,
smr000059142
arkadin
cevanol
neurobenzil
tranquilline
cafron
ay-5406
ethanol, benzilate hydrochloride
.beta.-diethylaminoethyl benzilate hydrochloride
amisil
ibiotyzil
aktozin
benzilic acid, 2-(diethylamino)ethyl ester hydrochloride
amizil
amisyl
nutinal
amyzyl
ay 5406-1
valladon
parasan
benzilic acid .beta.-diethylaminoethyl ester hydrochloride
benactyzine chloride
2-diethylaminoethyl benzilate hydrochloride
neuraktil
stoikon
nsc-16339
prokalm
2-(difenyl-hydroxyacetoxy)ethyl-diethylammoniumchlorid
amitakon
procalm
nervatil
valladan
amioyl
phobex
win 5606
cedad
diphenylglycollic acid 2-(diethylamino)ethyl ester hydrochloride
amizyl hydrochloride
parpon
nsc16339
benzilate du diethylamino-ethanol chlorhydrate
destendo
amysyl
amizil hydrochloride
57-37-4
suavitil
lucidil
benactyzine hydrochloride
fobex
parazan
katron
leucidil
benactizine hydrochloride
wln: qxr&r&vo2n2&2 &gh
2-diethylaminoethyl diphenylglycolate hydrochloride
nervacton
benaktin
benzilic acid, 2-(diethylamino)ethyl ester, hydrochloride
benzeneacetic acid, alpha-hydroxy-alpha-phenyl-, 2-(diethylamino)ethyl ester, hydrochloride
benzilate du diethylamino-ethanol chlorhydrate [french]
neuroleptone
ai3-26379
nsc 16339
ea 2092
morcain
benactyzin [czech]
ethanol, 2-(diethylamino)-, benzilate hydrochloride
benzilic acid beta-diethylaminoethyl ester hydrochloride
2-diethylaminoethylester kyseliny benzilove hydrochlorid [czech]
beta-diethylaminoethyl benzilate hydrochloride
2-(difenyl-hydroxyacetoxy)ethyl-diethylammoniumchlorid [czech]
einecs 200-324-4
2-(diethylamino)ethyl benzilate hydrochloride
B0053
benzilic acid 2-(diethylamino)ethyl ester hydrochloride
2-diethylaminoethyl 2-hydroxy-2,2-diphenylacetate hydrochloride
benzeneacetic acid, alpha-hydroxy-alpha-phenyl-, 2-(diethylamino)ethyl ester, hydrochloride (1:1)
benactyzine hcl
26r628272q ,
2-diethylaminoethylester kyseliny benzilove hydrochlorid
unii-26r628272q
MLS001424153
2-(diethylamino)ethyl 2-hydroxy-2,2-diphenylacetate hydrochloride
S3701
CCG-101069
FT-0612170
AKOS015901413
benzeneacetic acid, .alpha.-hydroxy-.alpha.-phenyl-, 2-(diethylamino)ethyl ester, hydrochloride
NC00319
benactyzine hydrochloride [who-dd]
ay-5406-1
benactyzine hydrochloride [mi]
benactyzine hydrochloride [vandf]
benactyzine hydrochloride [mart.]
benzeneacetic acid, .alpha.-hydroxy-.alpha.-phenyl-, 2-(diethylamino)ethyl ester, hydrochloride (1:1)
SCHEMBL4419579
DTXSID8052774
CHEMBL1584883
HY-B1542A
CS-8073
AC-32563
OPERA_ID_144
mfcd00012624
57-37-4 (hcl)
benactyzine hydrochloride, >=98% (hplc)
DS-11395
Q27254124
D88595
2-(diethylamino)ethyl 2-hydroxy-2,2-diphenylacetate;hydrochloride
SY057330
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.35480.003245.467312,589.2998AID2517
Chain A, Beta-lactamaseEscherichia coli K-12Potency39.81070.044717.8581100.0000AID485294
Smad3Homo sapiens (human)Potency0.10000.00527.809829.0929AID588855
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency79.43280.035520.977089.1251AID504332
DNA polymerase betaHomo sapiens (human)Potency79.43280.022421.010289.1251AID485314
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency0.12590.00419.962528.1838AID2675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1147960Octanol-phosphate buffer partition coefficient, Kp of the compound at pH 7.41977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Synthesis and preliminary pharmacological activity of aminoalkoxy isosteres of glycolate ester anticholinergics.
AID1147961Central dopaminergic activity in New Zealand rabbit assessed as change in colonic temperature at 5 mg/kg, iv measured every 15 mins for 2 hrs by thermistor probe attached telethermometric analysis1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Synthesis and preliminary pharmacological activity of aminoalkoxy isosteres of glycolate ester anticholinergics.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's4 (57.14)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]